Duchenne muscular dystrophy (DMD) is an X linked recessive condition affecting 1 in 3000 males.' Affected boys are normally wheelchair bound by the age of 11 or 12 years and die in their late teens. Patients suffering from the clinically milder form of disease, Becker muscular dystrophy (BMD), go into a wheelchair much later and may have a normal life span. These disease loci were thought to lie within Xp2l on the human X chromosome from cytogenetic observations of females suffering from the disease with balanced X;autosome translocations (for review see Elejalde and Elejalde2). The breakpoints of these translocations lie within the Xp2l band but have been shown to be heterogeneous.3 Studies using DNA markers confirmed the localisation of DMD to Xp2l and placed BMD in the same region. [4] [5] [6] Carrier detection and prenatal diagnosis of these disorders has been greatly improved by the use of restriction fragment length polymorphisms ( to remove parts of the gene such that if the processing of the transcript remains in a phase for translation a functional protein can be produced. This protein of course will not be as efficient in its action as the normal gene product. In cases of severe DMD the deletion must severely affect the integrity of the protein product and in some cases it might completely inhibit the production of protein. The exact mechanisms of these processes must await the determination of the breakpoints and the exons of the gene involved in the deletions.
One of the striking results reported here is the clinical presentation of patient 324 who possesses a deletion of at least 110 kb and yet is very mildly affected. From the knowledge of the exons present in this region of the gene, this patient must be missing at least four coding regions of the protein. Thus he must be able to cope with a truncated protein or have some way of compensating very efficiently for the lack of production of the DMD gene product. We are currently using cDNA clones to map and sequence his deletion endpoints.
The identification of mild patients who may be producing smaller proteins than normal males may allow us to characterise the smallest possible functional unit of this unusual protein. In this way we hope to be able to gain some insights into the disease pathology and possible therapies for this disorder in the future. 
